Patent SG-11201807474S-A (SG)
Title: Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
Inventor: DU JIALI
IPC: C07K16/28
Filed: 2017-04-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111111111111111111100111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/189433 Al 02 November 2017 (02.11.2017) W I PO I PCT (51) International Patent Classification: (74) Agent: MENSAH, Kwame, N. et al.; C/o Medimmune, A61K 39/395 (2006.01) C07K 16/28 (2006.01) LLC, One A61P 35/00 (2006.01) (US). Medimmune Way, Gaithersburg, MD 20878 (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/029143 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 24 April 2017 (24.04.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/327,214 25 April 2016 (25.04.2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: MEDIMMUNE, LLC [US/US]; One Medim- mune Way, Gaithersburg, MD 20878 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors: DU, Jiali; C/o Medimmune, LLC, One Medim- LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, GM, KE, mune Way, Gaithersburg, MD 20878 (US). SHAH, Am- UG, ZM, — barish; C/o Medimmune, LLC, One Medimmune Way, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Gaithersburg, MD 20878 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = Title: COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-Ll AND ANTI-CTLA-4 ANTIBODIES = (54) = = FIG. 1 = SEC Purity at 5!C = in0.0 = _ 99.5 = - = 99.0 a- = = : 5 = 90.5 o. * = _ = 98.0 _ • treme a tori 0 durvatreme =10:1 = 0 &mamma =15:1 4 durva:tretne =15:10 97.5 11 durvadreme . 1't1:1 El durvaftreme 40:3 A durva atone 1-1 97,0 E i 5 9. 1 1 I5 18 21 2A 27 30 en Time (mo nth) en 71' 01 GC 1-1 ----- (57) : Provided herein are compositions comprising coformulation of anti-PD-Ll and anti-CTLA-4 antibodies, or antigen-bind- 1-1 ing fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-PD- © Ll antibody durvalumab (MEDI4736) and the anti-CTLA-4 antibody tremelimumab are provided. ei O [Continued on next page] WO 2017/189433 Al MIDEDIMOMOIDEIROIDEMOMMEIMOHINDOMEHOM TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))